Purpose: This study compared the relative incidence of treatment-related toxicities and the event-free and overall survival between Hispanic and non-Hispanic children undergoing therapy for acute lymphoblastic leukemia (ALL) on Dana-Farber Cancer Institute ALL Consortium protocol 05-001.
INTRODUCTION
Despite overall cure rates near 90% in childhood acute lymphoblastic leukemia (ALL), survival in Hispanic children and adolescents with ALL remains inferior to survival in non-Hispanic patients. [1] [2] [3] [4] These disparities are particularly striking in light of dramatic improvements in survival for all children with ALL over the past three decades. 5, 6 In a large retrospective analysis from 12 Children's Cancer Study Group ALL trials (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) , 5-year event-free survival (EFS) was significantly lower in Hispanic children (65.9 ± 1.5%) when compared with 5-year EFS in white (72.8 ± 0.6%) and Asian children (75.1 ± 3.5%; P < 0.001). 7 More recent studies, including a Surveillance Epidemiology and End Results investigation of survival trends in ALL (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) , have revealed a persistent survival difference (5-15 percentage points) between Hispanic and non-Hispanic children. 1 The reasons for reduced survival in Hispanic children with ALL in North America are multifactorial and likely include both biologic and nonbiologic factors, such as differences in the frequency of high-risk leukemia subtypes, host pharmacogenomics, reduced access to care, and nonadherence to oral chemotherapy. 8 Differences in survival outcomes between Hispanic and nonHispanic patients with ALL have been described. 1, [9] [10] [11] Fewer studies have investigated whether the incidence of treatment-related toxicities (TRT) during ALL therapy varies by self-reported ethnicity, and none have described both survival and TRT in the same cohort. 9, 12, 13 The development of serious TRTs may result in an inability to tolerate full-dose chemotherapy, and the consequent interruptions in planned therapy (treatment delays, dose reductions) could theoretically contribute to increased risk of relapse. Conversely, development of very few TRTs might indicate lower overall drug exposure, either due to genetic polymorphisms affecting drug metabolism or to nonbiologic factors, such as chemotherapy nonadherence. We conducted an analysis of TRTs and survival in Hispanic and non-Hispanic children and adolescents undergoing treatment for newly diagnosed ALL on the Dana-Farber Cancer Institute ALL Consortium protocol 05-001 (DFCI 05-001). 14 We sought to compare the relative incidence of TRTs, EFS, and overall survival (OS) between these two patient cohorts.
Because common genetic variants are associated with risk of TRT, 15, 16 we also explored whether the prevalence of these polymorphisms in our patient population differed by ethnicity.
METHODS

Patients and eligibility criteria
Children and adolescents aged 1-18 years with newly diagnosed ALL were enrolled on DFCI 05-001 at 11 sites in Canada and the United States including Puerto Rico. Patients whose ethnicity was documented at the time of study enrollment were eligible for inclusion in this analysis. The Institutional Review Board of each participating institution approved the original treatment protocol and informed consent was obtained from each patient's guardian. All enrolled patients with known ethnicity (Hispanic and non-Hispanic) were included in the induction toxicity analysis. Patients with a documented complete remission (CR), final risk group, and treatment assignment were included in postinduction treatment analyses. For the investigation of targeted genetic variants, patients who met the above criteria and who also had genomic DNA available for analysis were included.
Ethnicity designation
Patient ethnicity (Hispanic or non-Hispanic) was documented at the time of study enrollment by a clinical research associate and was based on patient/parent report and/or patient's country of origin, as was the standard during the period in which the clinical trial was conducted. 17 Ethnicity designation was guided by the national standards for the classification of federal data on race and ethnicity as defined by the Office of Management and Budget Statistical Policy Directive No. 15. 18 Patients were categorized as underweight, normal, overweight, and obese based on body mass index (BMI).
For outcome analyses, patients were categorized as obese (BMI ≥ the 95th percentile for age and sex) versus not obese (BMI < 95th percentile).
Therapy
Details of the DFCI 05-001 treatment regimen have been previously published. 14 In brief, all patients underwent multiagent remission induction followed by risk-adapted postinduction therapy based on final risk group assignment. Final risk group was based on age, presenting leukocyte count, immunophenotype, presence or absence of leukemia in the cerebrospinal fluid at diagnosis, leukemia-associated cytogenetic abnormalities, and end-induction levels of minimal residual disease (MRD). All patients were scheduled to receive 24 months of postinduction treatment. Patients were eligible to participate in a randomized comparison of intramuscular native Escherichia coli L-asparaginase and intravenous pegaspargase during postinduction treatment. Patients who declined to participate, and those enrolled onto the trial after the randomized comparison had met its target accrual, were directly assigned to receive native E. coli L-asparaginase.
Toxicity assessment
Treatment-related toxicities were defined using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 and included bone fracture (all grades), grade 2 or worse osteonecrosis (ON), grade 3 or worse infection (bacterial, fungal, viral, and/or pneumocystis pneumonia), and grade 2 or worse asparaginase-associated toxicities (allergy, pancreatitis, thrombosis, or bleeding). 14 A diagnosis of bone fracture or ON required both clinical symptoms and radiographic confirmation.
Study staff at each participating institution prospectively collected TRT data at the time of CR, every 3 months subsequently until treatment completion, and annually thereafter.
Analysis of genetic variants
We conducted a secondary analysis of genomic data that were gathered for a separate correlative study looking at toxicities in the same study population. In this study, toxicities were not analyzed by ethnicity. Genomic DNA was isolated from peripheral blood collected after patients achieved CR. Nineteen candidate genetic variants were selected for investigation through a nonexhaustive literature review, with the following criteria: (1) variants present in genes related to pathways presumed to be relevant to TRT; (2) variants known to be associated with altered function of the gene product; and (3) variants with a population prevalence of at least 10%. 15, 16 Single nucleotide polymorphisms (SNPs) were detected using PCR-based allelic discrimination assays (Life Technologies, Grand Island, NY). The number of 28-bp repeats in the 5 ′ untranslated region of the thymidylate synthase (TS) gene was determined by PCR-product length analysis, as previously described. 15 
Statistical methods
Toxicity rates during induction and postinduction therapy were compared between groups with the Fisher's exact test. In patients who were assigned a final risk group after achieving CR, ON and bone fracture with follow-up information were analyzed within age subgroups (<10 years vs. ≥10 years). The cumulative incidences of ON and fracture were estimated with the cuminc utility in the "cmprsk" package in R and were tested using the Gray test, with relapse and death in remission identified as competing risks. Time-to-event was calculated as the time (years) from remission date to the date of first event. If the bone event occurred in induction, it was considered an event at time 0. The cumulative incidence was also modeled in univariate and multivariable analyses using competing risks regression. Multivariable models were adjusted for sex, asparaginase randomization, and final risk group. The grouping used in modeling for final risk group classification varied by age due to the protocol definition of age >10 as high risk. 14 OS and EFS were estimated with the Kaplan-Meier method and were compared between groups with the log rank test. OS was defined as the time from registration to death from any cause. EFS was defined as the time from registration to the first event of relapse, death, or second malignancy. Induction events, including death and/or failure to achieve CR, were considered events at time 0. Cox proportional hazards models were used to model OS and EFS by group univariately and were adjusted in multivariable analyses for diagnostic age, immunophenotype, white blood cell (WBC), obesity, and sex. In patients receiving a single full dose of IV pegaspargase, a Wilcoxon rank sum test was used to compare the serum asparaginase activity (SAA) between Hispanic and non-Hispanic patients at days 4, 11, 18, and 25 during induction.
The association between ethnicity group and SNPs were analyzed with the Fisher's exact test. A false discovery rate, using the method of Benjamini and Hochberg, 19 was used to adjust for multiple comparisons. Comparisons P adjusted < 0.05 were considered significant.
Additionally, an exploratory analysis was conducted to assess the univariate association between SNPs and toxicity (overall infection, pancreatitis, thrombosis, and allergy) within the ethnicity group. The relationship between EFS and SNPs within these groups was also explored. (Table 1) . Hispanic patients were significantly less likely to have the ETV6-RUNX1 fusion (P = 0.018). Presenting leukocyte count, immunophenotype, National Cancer Institute risk group, final DFCI risk group, or assigned randomized treatment arm (Table 1) did not significantly differ by ethnicity. 
RESULTS
Patient characteristics
TA B L E 1 Demographic and clinical characteristics of study participants on DFCI 05-001
Treatment-related toxicities 3.2.1 Infection
The overall rate of infection during the induction treatment phase was not significantly different between Hispanic and non-Hispanic patients (25 vs. 29%, P = 0.36). Hispanic patients trended toward having fewer bacterial infections than non-Hispanic patients (19 vs. 27%), but this difference was not statistically significant (P = 0.07) ( Table 2) . Postinduction infections were documented in 31% of Hispanic patients and in 32% of non-Hispanic patients (P = 0.92) ( Table 2 ).
Asparaginase-associated toxicities
The overall incidence of postinduction asparaginase-associated toxicities including allergy, pancreatitis and thrombosis, was not significantly different between Hispanic and non-Hispanic patients ( Table 2 ). The rate of ON and fracture during postinduction therapy was lower in Hispanic patients (P = 0.013 and <0.0001, respectively) ( Table 2) .
Serum asparaginase activity
At least one induction SAA level was available in 318 patients. During remission induction, when all patients received a single dose of pegasapargase, we did not observe differences between Hispanic and nonHispanic patients in median SAA levels at 4, 11, 18, and 25 days after the dose (Supplementary Fig. S1 ).
Osteonecrosis
Overall, the incidence of ON differed by age (P < 0.0001) with patients ≥10 years having more events. In patients ≥10 years of age, His- 
Fracture
In patients ≥10 years of age, there was no significant difference frac- Fig. 1D ). This remained significant in multivariable modeling (P = 0.0003; Table 3 ). In competing risks regression, there was no detectable difference in cumulative incidence of fracture by obesity for each age group (Table 3) .
Survival
The median follow-up time for those still alive was 6.12 years. Table S1 ).
There were no detectable differences in the site of relapse between groups (Supplementary Table S2 ). Of the B-ALL patients with a documented CR, there was no statistically significant difference in the proportion of patients with high end-induction MRD (defined as ≥10 −3 ):
Hispanic (11%) vs. non-Hispanic (9%), P = 0.55. Additionally, there was no difference in incidence of treatment-related mortality or in incidence of second malignant neoplasm between Hispanic and nonHispanic patients. Ethnicity retained significance in multivariable Cox modeling for EFS (P = 0.030) when adjusting for age, WBC, sex, immunophenotype and obesity, and marginal significance (P = 0.07) in multivariable modeling for OS when adjusting for the same variables.
In the multivariable models, obesity was significantly associated with OS (P = 0.012) but EFS (P = 0.27) ( Table 4) .
Polymorphisms
Genotyping data were available for 587 patients with ethnicity information tested whether there was also a significant difference in the prevalence of a polymorphism in TS known to be associated with bone toxicity. 16 In addition, we tested whether there were disparities associated with ethnicity for 18 other TRT-related polymorphisms previously assessed in this cohort. 15 Hispanic and non-Hispanic patients differed significantly in the proportion with the target genotype of four polymorphic genes: MTHFR A1298C (rs1801131;
and TCN2 (P adjusted = 0.002) (Supplementary Table S3 ). Of these four polymorphisms, only TCN2 was associated with both TRT and disease outcome. In Hispanic patients, having (vs. not having) the target TCN2 genotype was associated with increased risk of induction infection (32 vs. 11%, P = 0.010). In the Hispanic cohort, the TCN2 polymorphism was univariately associated with EFS within the Hispanic patient cohort. In multivariable modeling, TCN2 was marginally associated with EFS (HR = 3.15, P = 0.047) (Supplementary Table S4 ). BMI group was regrouped to obese versus not obese to account for overlap between obesity and overweight categories. No differences were seen with EFS. Adjusting for other variables, obesity remains significant and ethnicity is marginally significant. WBC, white blood cell; B-ALL, B-cell acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia.
TA B L E 4 Cox proportional hazards univariate and multivariable models of overall survival (OS) and event-free survival (EFS) by ethnicity
DISCUSSION
This analysis of TRTs and survival from DFCI ALL 05-001 demonstrated that overall, Hispanic patients had lower rates of ON and fracture as well as reduced EFS and OS relative to non-Hispanic patients.
The observation of both reduced toxicity and decreased survival in the Hispanic cohort suggests that host and/or environmental factors, rather than differences in leukemia biology alone, likely contributed to these outcomes.
In our Hispanic cohort, the lower incidence of skeletal toxicity is suggestive of reduced exposure to dexamethasone, which may be related to variations in medication adherence or to variations in disease biology or host pharmacogenomics. A potential mechanism of reduced dexamethasone exposure is oral chemotherapy adherence.
Chemotherapy agents that need to be orally administered at home, including mercaptopurine and corticosteroid, are important components of the treatment regimen for children and adolescents with ALL. 17, 22 In a 2012 report from the Children's Oncology Group, Bhatia and colleagues found that patients who were <95% adherent to mercaptopurine during maintenance therapy had a 2.5-fold higher risk of relapse than those who were ≥95% adherent. 23 Further analyses revealed that Hispanic ethnicity, adolescent age ≥12 years, and low socioeconomic status were all associated with lower adherence. 23 Of interest, in patients with high adherence, Hispanic ethnicity was still associated with higher relapse rate. This further emphasizes the possibility that differential findings between Hispanic and non-Hispanic patients are likely driven in large part by biologic differences between groups, rather than only by differences in adherence. In 2012, Kawedia et al. reported that dexamethasone clearance may be higher in patients with antiasparaginase antibodies. In that study, the increased clearance and/or the presence of the antibodies were associated with a higher risk of relapse. 24 Although we did not prospectively assess asparaginase antibodies on the 05-001 study, we serially measured SAA in patients during treatment, 25 and demonstrated no differences in SAA between Hispanic and non-Hispanic patients, indicating similar exposure to this agent by the ethnic group.
Having identified reduced rates of ON in Hispanic patients, we were particularly interested in whether there were differences between cohorts in the frequency of an enhancer-repeat genotype (2R/2R) polymorphism in the TS gene. 16, 26 Our analysis did not identify a difference in prevalence of the 2R/2R TS polymorphism between Hispanic and non-Hispanic patients, suggesting that either untested germline genetic factors or other variables beyond genetic polymorphisms may have contributed to differences in skeletal toxicities. [27] [28] [29] The incidence of ON was significantly different between Hispanic and nonHispanic patients in the older (≥10 years of age) patients, and the incidence of fracture was significantly different between Hispanic patients and non-Hispanic patients in the younger (<10 years of age) group.
The association between older age and ON in ALL patients has been well documented, as has the association between fracture and younger age. 30, 31 To our knowledge, no published study has identified a clear explanation for this phenomenon. Possible mechanisms may include hormonal interactions related to older age, timing of skeletal development, and unidentified genetic predispositions. Further, while obesity is a known predictor of reduced bone mineral density in children without leukemia, 32 it was not significantly predictive of either fracture or ON in our patient cohort and would not explain difference by age.
While host genetic variations likely play an important role in determining drug pharmacokinetics and pharmacodynamics, somatic abnormalities in leukemia cells are critical determinants of response and resistance to therapy as well. Differences in the frequency of prognostically significant subtypes of ALL between Hispanic and non-Hispanic patients have been described, some of which could explain some of the outcome differences we observed. 11, 33 For example, we observed a significantly lower incidence of the favorable ETV6-RUNX1 (TEL/AML1) fusion, in our Hispanic cohort, which may have contributed to a higher risk of relapse. 34 We 15, 16 and others 20, [35] [36] [37] [38] [39] [40] have previously described associations between functional genetic polymorphisms and TRT or survival among children with leukemia and the prevalence of some of these polymorphisms is known to differ between ethnic groups. 11, 20, 33, [41] [42] [43] In exploratory analyses, we targeted a small subset of polymorphisms that were relatively common (population prevalence of at least 10%)
and that could potentially impact either TRT or survival. We observed significant differences between Hispanic and non-Hispanic patients in the prevalence of four of the 19 polymorphisms analyzed (Supplementary [45] [46] [47] [48] For future studies, we will define both race and ethnicity using patient report, and will define genetic or biogeographical ancestry using modern genomic techniques. 33, 44 Comparing self-reported ethnicity to genetic ancestry will be an important part of investigating whether biology, sociocultural influences, or both are contributing to observed outcome differences between ethnically distinct populations. 49 
CONCLUSION
Hispanic children and adolescents enrolled on the DFCI 05-001 had significantly lower rates of skeletal toxicities as well as significantly lower EFS and OS compared to non-Hispanic patients. Hispanic patients were more frequently obese than non-Hispanic patients and obesity was associated with inferior OS, it did not explain differences in ON, fracture, or EFS by ethnicity. It is likely that the mechanisms behind our observations are a combination of biogeographical variables (i.e., inherited host genetic factors), gene-environment interactions, and sociocultural variables (i.e., early childhood exposures, baseline nutrition, health beliefs). [50] [51] [52] Other studies have compared self-defined ethnicity to genetic ancestry in childhood ALL, and have explored how these groups associate with relapse and adverse events. 53 Our combined analyses of disease outcomes and toxicity in a homogeneously treated patient population suggest that factors beyond genomics are involved. Considering the observation of both reduced toxicities and inferior survival in the Hispanic cohort, the possibility of suboptimal drug exposure in these patients likely deserves further inquiry. Thus, while differences in both host and leukemia biology are prognostically important, future studies will also focus on host pharmacogenomics, detailed analyses of nutrition status and obesity trends, 54 interpatient differences in biomarkers of drug exposure, frequency of drug interruptions for toxicity, and oral chemotherapy adherence.
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